These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35290044)

  • 1. Marine Natural Products as Leads against SARS-CoV-2 Infection.
    Chhetri BK; Tedbury PR; Sweeney-Jones AM; Mani L; Soapi K; Manfredi C; Sorscher E; Sarafianos SG; Kubanek J
    J Nat Prod; 2022 Mar; 85(3):657-665. PubMed ID: 35290044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbial Natural Products with Antiviral Activities, Including Anti-SARS-CoV-2: A Review.
    Frediansyah A; Sofyantoro F; Alhumaid S; Al Mutair A; Albayat H; Altaweil HI; Al-Afghani HM; AlRamadhan AA; AlGhazal MR; Turkistani SA; Abuzaid AA; Rabaan AA
    Molecules; 2022 Jul; 27(13):. PubMed ID: 35807550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target-Specific Drug Discovery of Natural Products against SARS-CoV-2 Life Cycle and Cytokine Storm in COVID-19.
    Lee M; Park J; Cho IH
    Am J Chin Med; 2022; 50(4):927-959. PubMed ID: 35729089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro.
    Silva RC; Freitas HF; Campos JM; Kimani NM; Silva CHTP; Borges RS; Pita SSR; Santos CBR
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
    Zhu Q; Zhang Y; Wang L; Yao X; Wu D; Cheng J; Pan X; Liu H; Yan Z; Gao L
    Antiviral Res; 2021 Mar; 187():105015. PubMed ID: 33444702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico evaluation of Philippine Natural Products against SARS-CoV-2 Main Protease.
    Cheng AJT; Macalino SJY; Billones JB; Balolong MP; Murao LAE; Carrillo MCO
    J Mol Model; 2022 Oct; 28(11):345. PubMed ID: 36205801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air-Liquid Interface Cultured Human Primary Bronchial Epithelial Cells.
    Ter Ellen BM; Dinesh Kumar N; Bouma EM; Troost B; van de Pol DPI; van der Ende-Metselaar HH; Apperloo L; van Gosliga D; van den Berge M; Nawijn MC; van der Voort PHJ; Moser J; Rodenhuis-Zybert IA; Smit JM
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting natural products against SARS-CoV-2.
    Al-Harrasi A; Behl T; Upadhyay T; Chigurupati S; Bhatt S; Sehgal A; Bhatia S; Singh S; Sharma N; Vijayabalan S; Palanimuthu VR; Das S; Kaur R; Aleya L; Bungau S
    Environ Sci Pollut Res Int; 2022 Jun; 29(28):42404-42432. PubMed ID: 35362883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising natural products against SARS-CoV-2: Structure, function, and clinical trials.
    Zhao Y; Deng S; Bai Y; Guo J; Kai G; Huang X; Jia X
    Phytother Res; 2022 Oct; 36(10):3833-3858. PubMed ID: 35932157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural Products as Potential Therapeutic Agents for SARS-CoV-2: A Medicinal Chemistry Perspective.
    Aggarwal V; Bala E; Kumar P; Raizada P; Singh P; Verma PK
    Curr Top Med Chem; 2023; 23(17):1664-1698. PubMed ID: 36974409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents.
    Nandi S; Roy H; Gummadi A; Saxena AK
    Curr Drug Targets; 2021; 22(17):2006-2020. PubMed ID: 33687893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural Products with Tandem Anti-inflammatory, Immunomodulatory and Anti-SARS-CoV/2 Effects: A Drug Discovery Perspective against SARS-CoV-2.
    da Cunha LNOL; Tizziani T; Souza GB; Moreira MA; Neto JSS; Dos Santos CVD; de Carvalho MG; Dalmarco EM; Turqueti LB; Scotti MT; Scotti L; de Assis FF; Braga AL; Sandjo LP
    Curr Med Chem; 2022; 29(14):2530-2564. PubMed ID: 34313197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial peptides: A promising tool to combat multidrug resistance in SARS CoV2 era.
    Saini J; Kaur P; Malik N; Lakhawat SS; Sharma PK
    Microbiol Res; 2022 Dec; 265():127206. PubMed ID: 36162150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyanobacterial natural products as sources for antiviral drug discovery against COVID-19.
    Jafari Porzani S; Konur O; Nowruzi B
    J Biomol Struct Dyn; 2022 Oct; 40(16):7629-7644. PubMed ID: 33749496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.
    Demarest JF; Kienle M; Boytz R; Ayres M; Kim EJ; Patten JJ; Chung D; Gandhi V; Davey RA; Sykes DB; Shohdy N; Pottage JC; Kumar VS
    Antiviral Res; 2022 Oct; 206():105403. PubMed ID: 36041646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.